2-(4-(trifluoromethyl)phenyl)-1,2-benzisothiazol-3(2H)-one | 78492-53-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-(trifluoromethyl)phenyl)-1,2-benzisothiazol-3(2H)-one
• 英文别名: 2-[4-(Trifluoromethyl)phenyl]-1,2-benzothiazol-3-one
• CAS: 78492-53-2
• 化学式: C₁₄H₈F₃NOS
• 分子量: 295.285
• InChiKey: YBISEFJDLUIDLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.07
• 重原子数：
  20.0
• 可旋转键数：
  1.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  22.0
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  2-(4-(trifluoromethyl)phenyl)-1,2-benzisothiazol-3(2H)-one 生成 1,1-dioxo-2-[4-(trifluoromethyl)phenyl]-1,2-benzothiazol-3-one
  参考文献：
  名称：

  JONES, H.;CLARK, R. L.;ZIMMERMAN, M.

  摘要：

  DOI：
• 作为产物：
  描述：

  2,2-二硫二苯甲酰氯 在 溴 作用下， 以 二氯甲烷 为溶剂， 生成 2-(4-(trifluoromethyl)phenyl)-1,2-benzisothiazol-3(2H)-one
  参考文献：
  名称：

  依布硒啉的生物立体研究：合成和体外表征1,2-苯并噻唑-3（2H）-一衍生物作为有效的新德里金属β-内酰胺酶抑制剂。

  摘要：

  产生新德里金属β-内酰胺酶（NDM-1）的耐碳青霉烯肠杆菌科（CRE）引起不可治愈的细菌感染，对人类健康构成重大威胁。在本研究中，通过采用依布硒啉硒部分的生物等位取代概念，我们设计，合成和表征了一个小分子的2取代1,2-苯并噻唑-3（2H）-衍生物和相关化合物的化合物库联合美罗培南评估其针对大肠杆菌Tg1（NDM-1）菌株的细胞毒性和协同活性。最有前途的化合物3a对FICI低至0.09的一组临床分离的NDM-1阳性CRE菌株显示出强大的协同活性。此外，分别通过酶抑制试验和ESI-MS分析证实了其IC50值和抑制机理。重要的是，化合物3a具有可接受的毒性并且不是疼痛。由于其结构简单和与美洛培南合用的有效协同活性，我们建议化合物3a可能是有前途的美洛培南佐剂，此类化合物的新系列可能值得进一步研究。

  DOI：

  10.1016/j.bioorg.2020.103873

文献信息

• Co-Catalyzed Intramolecular S-N Bond Formation in Water for 1,2-Benzisothiazol-3(<i>2H</i> )-ones and 1,2,4-Thiadiazoles Synthesis
  作者：Liting Yang、Lijuan Song、Shanyu Tang、Longjia Li、Heng Li、Bingxin Yuan、Guanyu Yang

  DOI：10.1002/ejoc.201801642

  日期：2019.2.14

  Sustainable synthesis of 1,2‐benzisothiazol‐3(2H)‐ones and 1,2,4‐thiadiazoles via intramolecular S‐N bond formation were realized in aqueous media with good to excellent yields, which used tetra‐sulfonated cobalt phthalocyanine as a catalyst and molecular oxygen as the environment friendly oxidant.

  在水介质中以良好或优异的产率实现了通过分子内S-N键形成可持续合成1,2-苯并噻唑-3（2H）-one和1,2,4-噻二唑的方法，该方法使用四磺化钴酞菁钴催化剂和分子氧作为环境友好型氧化剂。
• Benzisothiazol-3-ones through a Metal-Free Intramolecular N-S Bond Formation
  作者：Ke Yang、Hao Zhang、Ben Niu、Tiandi Tang、Haibo Ge

  DOI：10.1002/ejoc.201801090

  日期：2018.11.1

  An efficient selectfluor‐promoted synthesis of benzoisothiazol‐3‐ones through a sequential N–S bond formation and C–S bond cleavage process was developed.

  通过连续的N–S键形成和C–S键裂解过程，开发了一种有效的由Selectfluor促进的苯并异噻唑-3-酮的合成方法。
• Preparation of benzisothiazolones from 2-bromobenzamides and sulfur under copper catalysis conditions
  作者：V. Krasikova、M. Katkevics

  DOI：10.1007/s10593-013-1193-5

  日期：2013.2

  A convenient two-stage method has been developed for preparing benz[d]isothiazol-3(2H)-ones from 2-bromobenzamides and sulfur in a one-pot process under copper catalysis conditions. The method is suitable for the synthesis of N-aryl-, benzyl-, and alkyl-substituted benzisothiazolones. The yields of the benzisothiazolones depend on the nature of the starting amide and can reach 91%.

  已经开发了一种方便的两步法，用于在铜催化条件下通过一锅法从2-溴苯甲酰胺和硫制备苯并[ d ]异噻唑-3（2 H）-一。该方法适合于合成N-芳基-，苄基-和烷基取代的苯并异噻唑酮。苯并异噻唑酮的产率取决于起始酰胺的性质，可以达到91％。
• [EN] METHODS AND COMPOUNDS TO TREAT SARS INFECTIONS<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR TRAITER LES INFECTIONS À SARS-COV-2
  申请人：UNIV CALIFORNIA

  公开号：WO2022081984A1

  公开（公告）日：2022-04-21

  This disclosure features chemical entities (e.g., a compound (e.g., a compound of Formula (I), (II), (III), or (IV)), or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit the main protease (MPro) of a coronavirus (e.g., SARS-CoV-2). Said chemical entities are useful, e.g., for treating a coronavirus infection (e.g., SARS-CoV-2 infection (e.g., COVID-19)) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

  本文披露了一些化合物（例如，化合物（例如，公式（I），（II），（III）或（IV）的化合物），或药物的可接受盐，和/或水合物，和/或共晶体，和/或化合物的药物组合），它们能够抑制冠状病毒（例如，SARS-CoV-2）的主要蛋白酶（MPro）。这些化合物可用于治疗受体（例如，人类）的冠状病毒感染（例如，SARS-CoV-2感染（例如，COVID-19））。本文还涉及含有相同化合物的组合物，以及使用和制备这些化合物的方法。
• Potent, Selective, and Orally Available Benzoisothiazolone Phosphomannose Isomerase Inhibitors as Probes for Congenital Disorder of Glycosylation Ia
  作者：Russell Dahl、Yalda Bravo、Vandana Sharma、Mie Ichikawa、Raveendra-Panickar Dhanya、Michael Hedrick、Brock Brown、Justin Rascon、Michael Vicchiarelli、Arianna Mangravita-Novo、Li Yang、Derek Stonich、Ying Su、Layton H. Smith、Eduard Sergienko、Hudson H. Freeze、Nicholas D. P. Cosford

  DOI：10.1021/jm101401a

  日期：2011.5.26

  We report the discovery and validation of a series of benzoisothiazolones as potent inhibitors of phosphomannose isomerase (PM), an enzyme that converts mannose-6-phosphate (Man-6-P) into fructose-6-phosphate (Fru-6-P) and, more importantly, competes with phosphomannomutase 2 (PMM2) for Man-6-P, diverting this substrate from critical protein glycosylation events. In congenital disorder of glycosylation type Ia, PMM2 activity is compromised.; thus, PMI inhibition is a potential strategy for the development of therapeutics. High-throughput screening (HTS) and subsequent chemical optimization led to the identification of a novel class of benzoisothiazolones as potent PMI inhibitors having little or no PMM2 inhibition. Two complementary synthetic routes were developed, enabling the critical structural requirements for activity to be determined, and the compounds were subsequently profiled in biochemical and cellular assays to assess efficacy. The most promising compounds were also profiled for bioavailability parameters, including metabolic stability, plasma stability, and permeability. The pharmacokinetic profile of a representative of this series (compound 19; ML089) was also assessed, demonstrating the potential of this series for in vivo efficacy when dosed orally in disease models.